Effect of Extubation on Respiratory Function (PULMOVISTA)

Electrical Impedance Tomography: Effect of Extubation on Functional Residual Capacity

The extubation phase is a risky period of anesthesia management. During this step, serious complications can arise: hypoxemia, laryngospasm, pharyngeal obstruction, pneumonia… In spite of these complications, extubation and its impact on respiratory function, particularly on the Functional Residual Capacity (FRC), remains poorly studied because of the difficulty to make bedside measurements.

The PulmoVista 500 is a clinical routine which provide effective non-invasive bedside measurements. It would be interesting to evaluate the impact of extubation on respiratory function, and more specifically FRC changes during and after extubation.

This study will allow a better physiopathological knowledge and a quality improvement patient extubation management.

Study Overview

• Status: Completed
• Conditions: Functional Residual Capacity
• Intervention / Treatment: Other: Functional residual capacity measure by electrical impedance tomography

Detailed Description

The aim of this study is to evaluate the variation of functional residual capacity and its distribution before and after extubation.

Patients with scheduled surgery and receiving general anesthesia with orotracheal intubation are included and the measurements will be performed in the post-interventional monitoring room (PICU). EELI data will be collected before extubation and then at T0, then T5, T10, T15 and T20 minutes. No subsequent follow-up is required.

• Study Type: Interventional
• Enrollment (Actual): 34
• Phase: Not Applicable

Contacts and Locations

Study Locations

• France
  • Var
    • Toulon, Var, France, 83100
      • Hôpital d'Instruction des Armées de Sainte Anne

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Patient over 18 years
• Patient in operating room for scheduled surgery
• Patient receiving general anaesthesia with orotracheal intubation
• Patient given written consent after information
• Patient covered by social security or equivalent regimen

Exclusion Criteria:

• Patient undergoing thoracic and spinal surgery, due to the presence of dressings that interfere with measurements,
• Patient who has undergone intracerebral surgery because of possible communication difficulties upon awakening,
• Patients with a body mass index (BMI) > 50 (measurements not possible)
• Pregnant or breastfeeding patient,
• Patient contraindicated to the use of a thoracic electroimpedancemetry technique: dressings, wounds, presence of a pacemaker, defibrillator or any other active implant.
• Patient deprived of liberty by a judicial or administrative decision or patient subject to a legal protection measure (guardianship, curatorship...)
• Patient in a period of exclusion from another research protocol
• Any other reason that, in the opinion of the investigator, could interfere with the evaluation of study objectives

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Functional residual capacity; Functional residual capacity measure during and after extubation	Other: Functional residual capacity measure by electrical impedance tomography; Patient functional residual capacity will be measured by electrical impedance tomography before extubation and then at 0, 10, 15 and 20 min after extubation.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
End Expiratory Lung Impedance (EELI)	EELI variation before and at different timepoints after extubation: T0, T5, T10, T15 and T20 (min).	Between 2 and 3 hours

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Tidal volume distribution	Percentage of tidal volume in the different regions of interest before extubation and at different timepoints after it: T0, T5, T10, T15 and T20 (min).	Between 2 and 3 hours
Tidal volume distribution depending on patient position	Percentage of tidal volume according to patient position: supine with or without proclivity, lateral or ventral decubitus	Between 2 and 3 hours
Tidal volume distribution depending on surgery type and duration	Percentage of tidal volume according to type and duration of surgery	Between 2 and 3 hours
Tidal volume distribution depending on ventilatory mode	Percentage of tidal volume according to the ventilatory mode: controlled ventilation, spontaneous ventilation with inspiratory assistance, spontaneous ventilation of extubated patient with or without oxygenation device	Between 2 and 3 hours

Collaborators and Investigators

• Sponsor: Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
• Investigators: Study Director: Clarisse LEGER, Nurse, Hôpital d'instruction des armées Sainte-Anne

Study record dates

Study Major Dates

• Study Start (Actual): November 5, 2021
• Primary Completion (Actual): June 30, 2022
• Study Completion (Actual): June 30, 2022

Study Registration Dates

• First Submitted: October 1, 2021
• First Submitted That Met QC Criteria: October 1, 2021
• First Posted (Actual): October 14, 2021

Study Record Updates

• Last Update Posted (Actual): April 13, 2026
• Last Update Submitted That Met QC Criteria: April 10, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Keywords: Electrical impedance tomography; Extubation; Functional residual capacity; Pulmovista; Respiratory function
• Additional Relevant MeSH Terms: Pathologic Processes; Respiratory Tract Diseases; Respiration Disorders; Pathological Conditions, Signs and Symptoms; Respiratory Aspiration
• Other Study ID Numbers: 2020-CHITS-001; 2021-A00785-36 (Other Identifier: Id RCB)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No